Publikationen
Unsere Forschungsergebnisse erscheinen in internationalen Publikationen in Peer-Reviewed Journals, außerdem in Kongressbeiträgen, Vorträgen und Postern und wissenschaftlichen Fachveranstaltungen.
Übersicht über unsere Publikationen
Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations
Huber S, Kornauth C, Hutter S, Meggendorfer M, Summerer I, Kern W, Haferlach T, Pohlkamp C, Hoermann G. Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations. Br J Haematol. 2026.
Mehr erfahrenPromoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
Han S, Haertle L, Munawar U, Truger M, Hainold AS, Lee CY, Kurian S, Verbruggen C, Nerreter S, Vogt C, Besant E, Rein N, Lehmann J, Köppel M, Tamamushi Y, Zhou X, Steinbrunn T, Haaf T, Küster B, Slaby O, Haferlach C, Einsele H, Rasche L, Waldschmidt J, Besse A, Driessen C, Besse L, Kortüm KM. Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma. Clin Epigenetics. 2026.
Mehr erfahrenThe ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases
Lu C, Matt GY, Paul R, Wang J, Sioson E, Gangwani K, Acić A, Willems A, Zaldívar Peraza A, Reilly C, Pölönen P, Gao Q, Li Q, Pounds SB, Zeng AGX, Li S, Nadarajah N, Brady SW, Iacobucci I, Haferlach T, Rose MC, Mullighan CG, Zhou X. The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases. Blood. 2026.
Mehr erfahrenLoss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy
Munawar U, Thurner J, Nerreter S, Nerreter T, Leipold AM, Han S, Verbruggen C, Gerhard-Hartmann E, Vogt C, Grams B, Kurian S, Besant E, Roth S, Weingart J, Eiring P, Truger M, Afrin N, Steinbrunn T, Tamamushi Y, Zhou X, Rein N, Lehmann J, Köppel M, Rosenwald A, Haferlach C, Hudecek M, Saliba AE, Rasche L, Sauer M, Einsele H, Kuster B, Waldschmidt J, Kortüm KM. Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy. Leukemia. 2026.
Mehr erfahrenMolecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
Lanino L, Hunter AM, Gagelmann N, Robin M, Dall'Olio D, Flamigni A, Sala C, Gurnari C, Wang YH, Pleyer L, Xicoy B, Montalban-Bravo G, Shih LY, Alsugair A, Fathima S, Gregorio C, Rollo C, Palomo L, Platzbecker AS, Asti G, Itzykson R, Sallman DA, Fariselli P, Kern W, Garcia-Manero G, Platzbecker U, Solé F, Diez-Campelo M, Maciejewski J, Bejar R, Thol F, Kroger N, Savona M, Fenaux P, Sanz G, Kordasti S, Santini V, Fontenay M, Zeidan AM, Komrokji RS, Haferlach T, Germing U, Castellani G, D'Amico S, Patnaik M, Ieva F, Solary E, Tefferi A, Padron E, Della Porta MG. Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia. J Clin Oncol. 2026.
Mehr erfahrenFlare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma
Waldschmidt J, Fandrei D, Hecker JS, Meggendorfer M, Truger M, Reinhard F, Shibru B, Högner M, Gebauer A, Köppel M, Müller H, Jung J, Teschner D, Topp MS, Purcarea A, Vučinić V, Haferlach T, Bassermann F, Platzbecker U, Einsele H, Haferlach C, Kortüm KM, Metzeler KH, Merz M, Götze KS, Rasche L. Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma. Leukemia. 2026.
Mehr erfahrenMyeloid Neoplasms With a t(5;12)(q31;p13) and an Associated ETV6::ACSL6 Gene Fusion Are Diagnostically Challenging and Have a Poor Prognosis
Balk B, Truger M, Walter W, Schauwvlieghe A, Lübke J, Haferlach T, Haferlach C, Reiter A, Stengel A. Myeloid Neoplasms With a t(5;12)(q31;p13) and an Associated ETV6::ACSL6 Gene Fusion Are Diagnostically Challenging and Have a Poor Prognosis. Genes Chromosomes Cancer. 2026.
Mehr erfahren